

**MENJONG SORIG PHARMACEUTICALS CORPORATION LTD.
THIMPHU, BHUTAN**

STATEMENT OF COMPREHENSIVE INCOME

for the Quarter ended 31st March, 2023

PARTICULARS	Note No.	As At	As At
		31-03-2023	31-03-2022
		(Nu.)	(Nu.)
REVENUE			
Sales	15	20,351,899.42	11,612,490.30
Other Income	16	387,025.56	453,363.57
Total Revenue		20,738,924.98	12,065,853.87
EXPENDITURE			
Changes in Finished Goods & Work-in-Progress	17	(39,837.07)	885,091.90
Raw Materials & Packaging Materials Consumed	18	5,942,550.81	2,451,431.71
Impairment of Trade Receivables	6	203,663.93	-
Manufacturing Expenses	19	379,485.96	486,067.37
Employee Benefit Expenses	20	5,960,491.00	5,934,961.00
Finance Cost	21	200.00	-
Depreciation & Amortization	01 & 02	2,382,841.46	2,212,358.62
Other Expenses	22	937,663.31	519,569.81
Total Expenditure		15,767,059.39	12,489,480.40
Profit/(Loss) before Tax		4,971,865.59	(423,626.53)
Tax Expense			
Current Tax		1,491,559.68	-
Net Profit/(Loss) for the Year		3,480,305.91	(423,626.53)
Other comprehensive income			
<i>Items that will not be reclassified to profit or loss</i>			
Remeasurements of post-employment benefit obligations		-	-
Income tax relating to above item		-	-
Other comprehensive income, net of tax		-	-
Total comprehensive income		3,480,305.91	(423,626.53)
Earnings per equity share			
Basic and diluted			
Notes on Financial Statements forms integral part of Accounts	20	1.91	(0.23)

This is the Statement of Comprehensive Income referred to in our report of even date.

Chairman

Chief Executive Officer

Director

Place : THIMPHU

Date : , 2022